Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China

Abstract

Background: Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been widely spread. We aim to investigate the clinical characteristic and allergy status of patients infected with SARS-CoV-2. Methods:Electronic medical records including demographics, clinical manifestation, comorbidities, laboratory data, and radiological materials of 140 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection, were extracted and analyzed.Results: An approximately 1:1 ratio of male (50.7%) and female COVID-19 patients was found, with an overall median age of 57.0 years. All patients were communityacquired cases. Fever (91.7%), cough (75.0%), fatigue (75.0%), and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities. Drug hypersensitivity (11.4%) and urticaria (1.4%) were self-reported by several patients. Asthma or other allergic diseases were not reported by any of the patients.Chronic obstructive pulmonary disease (COPD, 1.4%) patients and current smokers (1.4%) were rare. Bilateral ground-glass or patchy opacity (89.6%) was the most common sign of radiological finding. Lymphopenia (75.4%) and eosinopenia (52.9%) were observed in most patients. Blood eosinophil counts correlate positively with lymphocyte counts in severe (r = .486, P < .001) and nonsevere (r = .469, P < .001) patients after hospital admission. Significantly higher levels of D-dimer, C-reactive protein, and procalcitonin were associated with severe patients compared to nonsevere patients (all P < .001). Conclusion:Detailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis. Allergic diseases, asthma, and COPD are not risk factors for SARS-CoV-2 infection. Older age, high number of comorbidities, and more prominent laboratory abnormalities were associated with severe patients.

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

“…Since it was first described in December 2019, more than seventy thousand cases of Corona Virus Disease 2019(COVID-19)have been confirmed，beyond two thousand patients of which were fatal [1][2][3][4]. So far, the infection keeps spreading, and more and more exported cases were confirmed in other provinces in China, and other countries.…”

“…Indicating that the disease is a serious threat to global health [5,6]. The management of patients with COVID-19 consists of a combination of supportive measures, antimicrobial therapy for any associated bacterial or viral infections, and strict implementation of appropriate infection control precautions [1][2][3][4].…”

Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)

“…Overall, 87 articles were initially identified based on our electronic and reference search, which after screening by tile, abstract, and full text, 80 were excluded as not related to COVID-19 (n=27), were review articles (n=7), did not provide relevant data (n=28), were editorials (n=10), did not provide data on severity or comorbidities (n=5), compared patients by mortality not severity (n=2) or compared mild cases to critical cases (n=1). Thus, a total number of 7 studies were finally included in our meta-analysis, totaling 1,592 COVID-19 patients, 314 of which (19.7%) had severe disease [6][7][8][9][10][11][12].…”

Patients with respiratory symptoms are at greater risk of COVID-19 transmission

“…The clinical and laboratory characteristics of hospitalized COVID-19 patients were described. 1,2 Cough is one of the most common symptoms at onset of illness. 3 Here, we described the differences in characteristics of nasopharyngeal swab detection between patients with and without respiratory symptoms.…”